Actelion Ltd (ATLN.VX)
56.65CHF
6:54am EDT
CHF-0.35 (-0.61%)
CHF57.00
CHF56.90
CHF57.50
CHF56.45
151,996
472,847
CHF60.00
CHF38.45
ATLN.VX
About
Overall
| Beta: | 0.58 |
| Market Cap (Mil.): | CHF7,226.06 |
| Shares Outstanding (Mil.): | 126.77 |
| Dividend: | 1.00 |
| Yield (%): | 1.75 |
Financials
| ATLN.VX | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 18.78 | 34.05 | 33.02 |
| EPS (TTM): | 3.03 | -- | -- |
| ROI: | 15.58 | -2.50 | 19.07 |
| ROE: | 22.66 | -3.10 | 20.00 |
UPDATE 1-Actelion gets go-ahead to continue new drug trial
* Selexipag is new drug for pulmonary arterial hypertension
Actelion gets go-ahead to continue new drug trial
ZURICH, May 8 - Actelion should continue a late-stage study into a new heart and lung drug, independent monitors have recommmended, with final results now expected by mid-2014, giving the biotech firm hope it has a further product in its pipeline.
Actelion shareholders reject biotech firm's pay plans
BASEL - Actelion shareholders rejected a $5.6 million pay award for the biotechnology company's chief executive Jean-Paul Clozel on Thursday, making it the second Swiss company in as many weeks to have its pay plans voted down by investors.
CORRECTED-UPDATE 1-Actelion shareholders reject biotech firm's pay plans
(Corrects par 3 to say holders of 55 percent of shares backed pay plan last year)
Actelion shareholders reject biotech firm's pay plans
* Influential shareholder groups had recommended 'no' vote
Actelion flags possible early return to profit growth
ZURICH - Actelion , Europe's largest biotech company, said it may return to profit growth sooner than expected after its first-quarter earnings more than doubled and sales of its mainstay drug beat expectations.
REFILE-UPDATE 2-Actelion flags possible early return to profit growth
ZURICH, April 16 - Actelion, Europe's largest biotech company, said it may return to profit growth sooner than expected after its first-quarter earnings more than doubled and sales of its mainstay drug beat expectations.
BRIEF-Shares in Actelion rise 3 pct after Q1 results
ZURICH, April 16 - Actelion Ltd : * Shares in Actelion rise 3 percent after Q1 results
Actelion first-quarter net profit beats expectations
ZURICH, April 16 - Europe's largest biotech company Actelion said it expected to publish an interim analysis of late-stage data for its heart and lung drug selexipag in coming weeks, as net profit in the first-quarter beat expectations.
BRIEF-Actelion gets Japanese nod for epoprostenol "ACT"
ZURICH, Feb 18 - Actelion Ltd : * Actelion Pharmaceuticals Ltd : Actelion obtains marketing approval for
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Wright Reports
|
$483.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
